Pharmaxis Ltd is an Australian pharmaceutical research company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue. Pharmaxis is developing its drug PXS-5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration has granted Orphan Drug Designation to PXS-5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that is scheduled to begin recruitment in Q1 2021. PXS‐5505 is also being investigated as a potential treatment for other cancers such as liver and pancreatic cancer.Other drug candidates being developed from Pharmaxis' amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and inflammatory diseases such as Duchenne Muscular Dystrophy. Pharmaxis has developed two products from its proprietary spray drying technology that are manufactured and exported from its Sydney facility; Bronchitol® for cystic fibrosis, which is approved and marketed in Europe, Russia and Australia; and Aridol® for the assessment of asthma, which is approved and marketed in the United States, Europe, Australia and Asia. Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia.

Website: pharmaxis.com.au

Employees: 100 - 249

HQ:

Location: Frenchs Forest, NSW, AU

Revenue: 5 - 10 Million

Are you looking for contact information for Pharmaxis? ConnectPlex is the right place to be! Our extensive database of company information includes contact details for Pharmaxis and millions of other companies across the globe. With our AI-based B2B lead generation products, you can easily find and connect with the right people at Pharmaxis to grow your business. Our database is regularly updated to ensure accuracy and relevance, so you can be confident that you're getting the most up-to-date contact information for Pharmaxis. And with our keyword-rich content, you can optimize your search engine rankings and increase your visibility to potential customers. ConnectPlex is the perfect solution for businesses looking to expand their reach and connect with new customers.

Pharmaxis: A Leader in BioTech and Drug Development Pharmaxis Ltd is a leading Australian pharmaceutical research company that specializes in developing drugs for inflammatory and fibrotic diseases. With a focus on myelofibrosis, a bone marrow cancer that leads to a build-up of scar tissue in the bone marrow, Pharmaxis has developed a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors. The company's drug candidate, PXS-5505, has been granted Orphan Drug Designation by the US Food and Drug Administration and is set to begin phase 1c/2 clinical trials in Q1 2021. In addition to its work in myelofibrosis, Pharmaxis is also developing drugs for other fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis, as well as inflammatory diseases such as Duchenne Muscular Dystrophy. The company's proprietary spray drying technology has also led to the development of two approved products, Bronchitol® for cystic fibrosis and Aridol® for the assessment of asthma. Pharmaxis has a strong track record of innovation and has been recognized for its contributions to the biotech industry. The company is listed on the Australian Securities Exchange (PXS) and has a team of experienced executives leading the way. With a focus on Undertreated Respiratory Diseases and Research and Development, Pharmaxis is poised to continue making a positive impact in the healthcare industry.

Pharmaxis is a company in Australia that works on creating medicines for people who have diseases that cause inflammation and scarring, like myelofibrosis, which affects the bone marrow. They have a special way of making drugs that works really well, and they have already made some medicines that are being used to help people. The company is also studying whether their medicines could work for other types of cancer, like liver and pancreatic cancer. They have another medicine that is being tested to see if it can help people with other diseases that cause scarring, like kidney disease, lung disease, and heart disease. Pharmaxis also makes two other products that are already being sold and used by people. One is for people with cystic fibrosis, and the other is for people with asthma. The company is listed on the Australian stock exchange and has its main office and research facilities in Sydney.